Prostate Cancer News and Research

Latest Prostate Cancer News and Research

IsoRay to sell $2.25 million in common stock

IsoRay Inc. has entered a securities purchase agreement with an investor to sell $2.25 million in common stock with the potential of $2,075,000 additional funding through two subsequent short term warrant tranches of 90 days and 180 days assuming an average exercise price of $1.40 and that all Series A and B warrants are exercised. Additional funding will occur if Series C or D warrants are exercised.

22 Nov 2010

Study finds no link between prostate cancer clinical stage and risk of recurrence after radical prostatectomy

A new study challenges the current staging system that determines the extent or severity of prostate cancer that has not metastasized. Published early online in CANCER, a peer-reviewed journal of the American Cancer Society, the study found that there is no link between localized prostate cancer's clinical stage and a patient's risk of cancer recurrence after having his prostate removed.

22 Nov 2010

Xgeva receives FDA approval for prevention of SREs in patients with bone metastases

The U.S. Food and Drug Administration approved Xgeva (denosumab) on Thursday to help prevent skeletal-related events (SREs) in patients with cancer that has spread (metastasized) and damaged the bone. Skeletal-related events include bone fractures from cancer and bone pain requiring radiation.

19 Nov 2010

ZIOPHARM announces data on darinaparsin efficacy for solid tumors at EORTC-NCI-AACR Symposium

ZIOPHARM Oncology, Inc. announced today important new preclinical data on the efficacy of darinaparsin (ZinaparTM, or ZIO-101) in various solid tumor models delivered at the EORTC-NCI-AACR International Symposium on Molecular Targets and Cancer Therapeutics being held in Berlin, Germany.

19 Nov 2010

ImmunoGen presents positive data on IMGN388 anticancer compound at EORTC-NCI-AACR Symposium

ImmunoGen, Inc., a biotechnology company that develops antibody-based anticancer products using its Targeted Antibody Payload (TAP) technology, today announced the presentation of encouraging clinical data for the Company's IMGN388 anticancer compound at the 22nd EORTC-NCI-AACR Symposium on Molecular Targets and Cancer Therapeutics taking place in Berlin, Germany.

19 Nov 2010

Threshold Pharmaceuticals announces results on TH-302 prodrug for cancers at EORTC-NCI-AACR Symposium

Threshold Pharmaceuticals, Inc. today announced clinical trial results related to Threshold's clinical stage hypoxia-activated prodrug, TH-302. The results were presented at the 22nd EORTC-NCI-AACR Symposium on Molecular Targets and Cancer Therapeutics taking place in Berlin, Germany from November 16 to19, 2010.

19 Nov 2010

DoD recommends funding for Synta's STA-9584 for prostate cancer study

Synta Pharmaceuticals Corp., a biopharmaceutical company focused on discovering, developing, and commercializing small molecule drugs to treat severe medical conditions, today announced that the Department of Defense (DoD) has recommended STA-9584, a novel vascular disrupting agent (VDA) currently in pre-clinical development at Synta, be funded for study in advanced prostate cancer.

19 Nov 2010

Mass. regulators and nursing homes fight inappropriate medicating; officials deal with Hawaii doctor shortage

State regulators and the Massachusetts nursing home industry are launching a campaign today to reduce the inappropriate use of antipsychotic medications for residents with dementia.

19 Nov 2010

Medicare committee recommends expensive drug for some prostate-cancer patients

A new treatment for prostate cancer called Provenge won a vote of confidence from a Medicare coverage advisory committee Wednesday, suggesting the federal program is likely to pay for the $93,000-per-patient medicine.

19 Nov 2010

Expert panel to endorse newly approved therapeutic vaccine for advanced prostate cancer

Provenge is one step closer to being covered by Medicare. An expert panel voted Wednesday to endorse the newly approved therapeutic vaccine for men with advanced prostate cancer.

19 Nov 2010

Women prefer diet advice from women: Study

A new study shows that women do not pay heed to diet advice from men. The study conducted by the Australian National University (ANU) suggests women are more inclined to listen and change their behaviour if the speaker is also female.

18 Nov 2010

Multidisciplinary clinic approach can improve survival in patients with aggressive prostate cancer

A research team from the National Cancer Institute (NCI) designated Kimmel Cancer Center (KCC) at Jefferson has concluded for the first time that a multidisciplinary clinic approach to aggressive prostate cancer can improve survival in patients. The results from the 15-year study of the multidisciplinary clinic can be found in the November issue of Journal of Oncology Practice.

18 Nov 2010

New anti-cancer drug targeting vitamin D receptor reduces PSA level in HRPC

A new anti-cancer drug aimed at vitamin D receptors on cancer cells has prompted encouraging responses in the levels of PSA (prostate specific antigen) in men with prostate cancer that has become resistant to hormonal therapies.

18 Nov 2010

MK-4827 drug candidate shows promising anti-tumour activity in first human trial

A new drug that targets proteins responsible for helping cancer cells to repair damage to their DNA has shown promising anti-tumour activity in its first trial in humans.

18 Nov 2010

Exelixis reports interim data of XL184 for metastatic castration-resistant prostate cancer

Exelixis, Inc. today reported interim data from the cohort of patients with metastatic castration-resistant prostate cancer (CRPC) treated with XL184 in an ongoing phase 2 adaptive randomized discontinuation trial (RDT).

18 Nov 2010

Exelixis reports interim data from phase 2 RDT trial for epithelial ovarian cancer

Exelixis, Inc. today reported interim data from the cohort of patients with advanced epithelial ovarian cancer, primary peritoneal, or fallopian tube carcinoma treated with XL184 in an ongoing phase 2 adaptive randomized discontinuation trial (RDT).

18 Nov 2010

Mayo Clinic to establish pencil beam proton scanning facilities in Minnesota, Arizona and Florida

Mayo Clinic today announced plans to establish the Mayo Clinic Proton Beam Therapy Program as part of Mayo's national three-site cancer center in Minnesota, Arizona and Florida. The new program will employ intensity modulated proton therapy — based on pencil beam scanning — which is a more precise form of proton therapy treatment that allows greater control over radiation doses, shorter treatment times and fewer side effects. It is also believed to be more cost effective in selected patients.

17 Nov 2010

Predictive Biosciences, Epigenomics extend GSTP1 licensing agreement for prostate cancer

Epigenomics AG , the cancer diagnostics company, and Predictive Biosciences, a commercial stage, fully-integrated developer of novel molecular diagnostic cancer assays and a provider of anatomic pathology laboratory products and services, today announced that they have extended their licensing agreement for the prostate cancer biomarker GSTP1, originally signed in April 2009.

17 Nov 2010

Enzon presents data on three investigational mRNA antagonists at EORTC-NCI-AACR Symposium

Enzon Pharmaceuticals, Inc. today presented data from preclinical studies of three investigational messenger RNA (mRNA) antagonists. These antagonists are based on the locked nucleic acid (LNA) technology platform targets licensed from Santaris Pharma A/S.

17 Nov 2010

Medicare roundup: Payment cuts irk healthcare industry; officials mull new prostate-cancer treatment

Doctors across the United States are taking a wait-and-see approach while Congress decides whether or not to allow a scheduled 23% cut in Medicare reimbursement rates to take effect on Dec. 1.

17 Nov 2010

Prostate Cancer News and Research

Latest Prostate Cancer News and Research

IsoRay to sell $2.25 million in common stock

Study finds no link between prostate cancer clinical stage and risk of recurrence after radical prostatectomy

Xgeva receives FDA approval for prevention of SREs in patients with bone metastases

ZIOPHARM announces data on darinaparsin efficacy for solid tumors at EORTC-NCI-AACR Symposium

ImmunoGen presents positive data on IMGN388 anticancer compound at EORTC-NCI-AACR Symposium

Threshold Pharmaceuticals announces results on TH-302 prodrug for cancers at EORTC-NCI-AACR Symposium

DoD recommends funding for Synta's STA-9584 for prostate cancer study

Mass. regulators and nursing homes fight inappropriate medicating; officials deal with Hawaii doctor shortage

Medicare committee recommends expensive drug for some prostate-cancer patients

Expert panel to endorse newly approved therapeutic vaccine for advanced prostate cancer

Women prefer diet advice from women: Study

Multidisciplinary clinic approach can improve survival in patients with aggressive prostate cancer

New anti-cancer drug targeting vitamin D receptor reduces PSA level in HRPC

MK-4827 drug candidate shows promising anti-tumour activity in first human trial

Exelixis reports interim data of XL184 for metastatic castration-resistant prostate cancer

Exelixis reports interim data from phase 2 RDT trial for epithelial ovarian cancer

Mayo Clinic to establish pencil beam proton scanning facilities in Minnesota, Arizona and Florida

Predictive Biosciences, Epigenomics extend GSTP1 licensing agreement for prostate cancer

Enzon presents data on three investigational mRNA antagonists at EORTC-NCI-AACR Symposium

Medicare roundup: Payment cuts irk healthcare industry; officials mull new prostate-cancer treatment

What to know about prostate cancer eBook

Redefining control and consistency in anaerobic microbiome workflows

AI in Healthcare: How generative tools are transforming clinical practice

The future of automation: Machine learning–driven hepatocyte and organoid counting

Prostate Cancer News and Research

Latest Prostate Cancer News and Research

What to know about prostate cancer eBook

Redefining control and consistency in anaerobic microbiome workflows

AI in Healthcare: How generative tools are transforming clinical practice

The future of automation: Machine learning–driven hepatocyte and organoid counting

Newsletters you may be interested in